ÂÜÀòÂÒÂ×

As Pfizer’s CDO, Dr. Cooperstone is responsible for advancing and managing the development portfolio of its rare disease business, including advanced technology platforms such as gene therapy. In addition, she is site leader for the company’s Collegeville campus.

Prior to her current role, Dr. Cooperstone held a variety of leadership positions at Pfizer in clinical development and global medical affairs, with oversight over a wide range of therapeutic areas, including small and large molecules in early through late phase development, and in-line support. She started her career in the pharmaceutical industry in 1999 at Wyeth Pharmaceuticals and joined Pfizer in 2009.

Dr. Cooperstone earned her M.D. from McGill University, and completed her residency in pediatrics at the Montreal Children’s Hospital, her clinical fellowship in pediatric nephrology at Children’s Hospital of Philadelphia and a research fellowship at the University of Pennsylvania’s Renal Electrolyte division. Dr. Cooperstone then practiced pediatric nephrology at Scottish Rite Children’s Hospital, a member institution of Children’s Healthcare of Atlanta, before joining the pharmaceutical industry in 1999.